Latest News

Wednesday, July 26, 2017 | Health Care, Prevent Blindness

Prevent Blindness Advocates for Essential Health Benefits That Include Children’s Vision Benefits

On July 25, the United States Senate voted 51-50, with the tie-breaking vote cast by Vice President Mike Pence, on a motion to proceed to consideration of legislation that would ultimately repeal the …

Read the full story

Wednesday, July 26, 2017 | Product Releases

OpTranslate Optometry Translation App Now Available on the Apple and Google Play App Stores

The Optranslate mobile app looks to help train eye care professionals into competent multilingual practitioners, expanding their range of practice and enhancing the doctor-patient relationship through…

Read the full story

Wednesday, July 26, 2017 | Clinical Trials,Earnings & Financials, AMD, Ophthotech

Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases

Ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for…

Read the full story

Wednesday, July 26, 2017 | Earnings & Financials, Kala Pharmaceuticals 

Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option

Kala Pharmaceuticals announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters’ exercise in full of their option to purchase an additio…

Read the full story

Wednesday, July 26, 2017 | Health Care

US Senate Narrowly Votes to Move Ahead With Debate on Affordable Healthcare Act Repeal

US Vice President Mike Pence cast a decisive vote Tuesday that swayed an evenly divided Senate to open debate on Republican-led attempts aimed at repealing the Affordable Healthcare Act. &qu…

Read the full story

Tuesday, July 25, 2017 | Medical Studies, American Academy of Ophthalmology

Scientists Zero In On Key Protein Driving HSV-1 Inflammation

Scientists from the University of Illinois at Chicago have identified the enzyme heparanase as the crucial factor involved in herpes simplex (HSV-1)-associated corneal inflammation. The heterodimer pr…

Read the full story

Tuesday, July 25, 2017 | Medical Studies,Retina, Alimera Sciences

New Data Reveal Real-World Benefits of Iluvien Treatment

Latest data from an ongoing audit of real-life UK clinical practice published online today in Eye show the number of chronic diabetic macular edema (DME) patients with 6/12 vision, DVLA’s minimu…

Read the full story

Tuesday, July 25, 2017 | Product Releases

Vance Thompson Vision First in the United States to Perform Cataract Surgery with Zepto

Vance Thompson Vision will be the first center in the United States to utilize Zepto in conjunction with Refractive Laser-Assisted Cataract Surgery, or ReLACS. This technology uses low-energy pulses t…

Read the full story

Tuesday, July 25, 2017 | Partnerships, AMD, Foundation Fighting Blindness

4D Molecular Therapeutics and Foundation Fighting Blindness Partner to Develop Gene Therapies for Retinal Diseases

4D Molecular Therapeutics (4DMT), a provider of adeno-associated virus (AAV) gene therapy vector discovery and product development, and the Foundation Fighting Blindness (FFB), the world’s large…

Read the full story

Monday, July 24, 2017 | Acquisitions/Mergers, Essilor

Antitrust Process Update for the Proposed Combination Between Essilor and Luxottica

The proposed combination between Essilor and Luxottica continues to progress, with the antitrust process advancing in all jurisdictions. Essilor and Luxottica have jointly filed with the antitrust aut…

Read the full story

Monday, July 24, 2017 | Clinical Trials,Glaucoma, BioLight

BioLight Reports Successful Results in Phase 1/2a Clinical Trial for Glaucoma Insert

BioLight Life Sciences announced successful results from its glaucoma insert VS101 (Eye-D latanoprost insert) phase 1/2a clinical trial, which demonstrated its ability to lower IOP for a 12-week perio…

Read the full story

Monday, July 24, 2017 | Medical Studies

Too Little Vitamin D May Hinder Recovery of Injured Corneas

Injury or disease in combination with too little vitamin D can be bad for the window to your eyes. The three-layer, transparent cornea at the front of the eyes focuses the light coming in. But its pro…

Read the full story

Monday, July 24, 2017 | Product Releases

Cenegermin Eye Drops For the Treatment of Neurotrophic Keratitis Receive European Union Approval

Dompe announced that the European Commission has granted the marketing authorization of cenegermin eye drops for the treatment of moderate to severe neurotrophic keratitis. This makes it the first bio…

Read the full story

Monday, July 24, 2017 | Acquisitions/Mergers

Private Equity-Backed Eyeconic Vision Partners Acquires Swagel-Wootton Hiatt Eye Center

Cortec Group, a New York-based private equity firm which invests in middle-market specialty healthcare, business-to-business and consumer products, and services businesses, announced that on July 6, 2…

Read the full story

Monday, July 24, 2017 | Earnings & Financials, Allegro Ophthalmics

Allegro Ophthalmics Secures $10.7 Million in Private Financing

Allegro Ophthalmics announced the completion of a private round of equity financing for $10.7 million. With this infusion of capital, the company is positioned to reach future corporate milestones. Th…

Read the full story
Load More
 Stock Price  Change 
 ADVM $2.60  0.00% 
 Aerie Pharmaceuticals, Inc. $54.70  -2.23% 
 Akorn, Inc. $33.63  -0.06% 
 Alimera Sciences, Inc. $1.45  0.00% 
 Allergan $256.15  0.60% 
 Applied Genetic Technologies $5.10  3.03% 
 Bayer $130.57  0.43% 
 Can-Fite Biopharma $1.82  1.68% 
 Clearside Biomedical $9.17  -1.40% 
 Cooper Companies, Inc. $247.01  -1.52% 
 Eleven Biotherapeutics $1.58  1.94% 
 Escalon Medical Corp. $0.18  0.06% 
 Glaukos $42.60  0.76% 
 Imprimis Pharmaceuticals, Inc. $2.64  -0.38% 
 Inotek Pharmaceuticals $0.96  -3.43% 
 IRIDEX Corporation $9.67  1.04% 
 Johnson & Johnson $130.95  -0.71% 
 Merck & Company, Inc. $61.80  -0.90% 
 NovaBay Pharmaceuticals, Inc. $0.18  5.88% 
 Novartis AG Common Stock $84.85  0.77% 
 Ocular Therapeutix $6.52  1.56% 
 Ophthotech Corporation $2.71  2.65% 
 Regeneron $515.63  0.42% 
 Roche $31.66  -0.44% 
 Second Sight Medical Products $1.24  2.48% 
 Shire $169.80  2.22% 
 STAAR Surgical Company $10.20  0.00% 
 TearLab Corporation $2.93  2.09% 
 Valeant Pharmaceuticals $17.77  0.34% 
 Xoma $7.38  2.07%